ARTICLE | Finance

IPOs on deck

Infectious disease play Trius and pain company NuPathe look to price biotech IPOs

August 2, 2010 7:00 AM UTC

Two biotechs look poised to make exits this week, including infectious disease company Trius Therapeutics Inc., which is anticipated to price its IPO on Tuesday, and NuPathe Inc., a neurology play expected to price at some point during the week.

Trius plans to sell 6 million shares at $12-$14 through underwriters Citigroup; Piper Jaffray; Canaccord; and JMP Securities. At the mid-point, Trius would raise $78 million and have a post-money valuation of $216.8 million...